RxDoctor Payments Data

Andrew Lee, MD

Internal Medicine · Arcadia, CANPI 1306868617

Payments from drug & device makers

$1,970in general payments, 2019–2025

Across 23 payments — averaging $85.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • AbbVie$201
  • Abiomed$183
  • Novo Nordisk$163
  • Pfizer$56
  • Covidien LP$38
  • plus $71 from 3 others

What the payments were for

  • Travel & lodging$1,25764%
  • Food & beverage$71236%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical4$1,257
AbbVie(2 entities)6$201
Abiomed2$183
Novo Nordisk3$163
Pfizer3$56
Covidien LP1$38
Merck2$25
Johnson & Johnson1$24
Nabriva Therapeutics, PLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,970 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$193,462
Medicare patients
410
Services billed
2,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban48$25,492
EliquisApixaban40$22,601
Spiriva RespimatTiotropium Bromide11$9,398
Breo ElliptaFluticasone/Vilanterol12$5,590
Memantine Hcl38$5,078
Famotidine41$4,422
Levothyroxine Sodium182$3,477
Wixela InhubFluticasone Propion/Salmeterol16$2,861
Ursodiol20$2,811
Rosuvastatin Calcium176$2,435
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid18$1,943
Amlodipine Besylate192$1,935
Atorvastatin Calcium202$1,578
SynthroidLevothyroxine Sodium17$1,522
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide20$1,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$24$25,49248 claims
PfizerEliquis$56$22,60140 claims
AbbVieSynthroid$201$1,52217 claims
Novo NordiskLevemir$163$1,30011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →